Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Alkaptonuria and ochronosis in three siblings. Ascorbic acid treatment monitored by urinary HGA excretion.

Forslind, K LU ; Wollheim, F A ; Akesson, B and Rydholm, U (1988) In Clinical and Experimental Rheumatology 6(3). p.289-292
Abstract
Patients with alkaptonuria lack homogentisate 1,2-dioxygenase leading to retention of homogentistic acid (HGA) in body fluids and eventually to tissue deposition of oxidation products, giving rise to the clinical picture of ochronosis. Ascorbic acid is a known inhibitor of the enzyme which catalyses the oxidation of homogentisic acid (HGA) to the polymer with affinity for collagen and was used in the treatment of three siblings with alkaptonuria. Ascorbic acid 500 mg bid was administered for 12 months. Two of the siblings tolerated the treatment, and in one the symptoms improved, whereas in the other they worsened. Plasma and urinary levels of HGA were monitored with a new HPLC method. Ascorbic acid is not effective in the treatment of... (More)
Patients with alkaptonuria lack homogentisate 1,2-dioxygenase leading to retention of homogentistic acid (HGA) in body fluids and eventually to tissue deposition of oxidation products, giving rise to the clinical picture of ochronosis. Ascorbic acid is a known inhibitor of the enzyme which catalyses the oxidation of homogentisic acid (HGA) to the polymer with affinity for collagen and was used in the treatment of three siblings with alkaptonuria. Ascorbic acid 500 mg bid was administered for 12 months. Two of the siblings tolerated the treatment, and in one the symptoms improved, whereas in the other they worsened. Plasma and urinary levels of HGA were monitored with a new HPLC method. Ascorbic acid is not effective in the treatment of symptomatic ochronosis. (Less)
Please use this url to cite or link to this publication:
author
; ; and
publishing date
type
Contribution to journal
publication status
published
in
Clinical and Experimental Rheumatology
volume
6
issue
3
pages
289 - 292
publisher
Pacini
external identifiers
  • scopus:0023816246
ISSN
1593-098X
language
English
LU publication?
no
id
260d45ab-8695-4227-be5a-7d3d8b6acfcc
date added to LUP
2019-06-28 15:05:04
date last changed
2021-12-27 04:52:51
@article{260d45ab-8695-4227-be5a-7d3d8b6acfcc,
  abstract     = {{Patients with alkaptonuria lack homogentisate 1,2-dioxygenase leading to retention of homogentistic acid (HGA) in body fluids and eventually to tissue deposition of oxidation products, giving rise to the clinical picture of ochronosis. Ascorbic acid is a known inhibitor of the enzyme which catalyses the oxidation of homogentisic acid (HGA) to the polymer with affinity for collagen and was used in the treatment of three siblings with alkaptonuria. Ascorbic acid 500 mg bid was administered for 12 months. Two of the siblings tolerated the treatment, and in one the symptoms improved, whereas in the other they worsened. Plasma and urinary levels of HGA were monitored with a new HPLC method. Ascorbic acid is not effective in the treatment of symptomatic ochronosis.}},
  author       = {{Forslind, K and Wollheim, F A and Akesson, B and Rydholm, U}},
  issn         = {{1593-098X}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{289--292}},
  publisher    = {{Pacini}},
  series       = {{Clinical and Experimental Rheumatology}},
  title        = {{Alkaptonuria and ochronosis in three siblings. Ascorbic acid treatment monitored by urinary HGA excretion.}},
  volume       = {{6}},
  year         = {{1988}},
}